Neurological-Behavioral Clinical Research — research payments reported

By program year

6 rows

Year	Kind	Amount	Payments
2025	Research	$128,211	77
2024	Research	$361,037	6
2023	Research	$22,650	4
2022	Research	$17,967	5
2021	Research	$71,364	17
2020	Research	$119,401	16

Breakdown

Who paid Research payments · program years 2020–2025

Boehringer Ingelheim International GmbH $507,989 83 payments
Biogen, Inc. $101,772 4 payments
Eisai Inc. $96,375 16 payments
Boehringer Ingelheim RCV GmbH & Co KG $7,891 18 payments
Boehringer Ingelheim Pharma GmbH & Co.KG $6,337 2 payments
Boehringer Ingelheim Pharmaceuticals, Inc. $267 2 payments

Studies the money was for Research payments · program years 2020–2025

Phase II DRF study of NR2B modulation in MDD $347,649 2 payments
A Phase II, 6-week, multicenter, randomized, double blind (patient and investigator) or masked, placebo controlled, dose-finding trial to evaluate the efficacy, tolerability, and safety of different doses of oral BI 1569912 as adjunctive therapy in MD $128,172 76 payments
A 52 Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Belviq XR??in Conjunction With Lifestyle Modification for Weight Loss in Obese Adolescents, Age 12 to 17 Years $96,375 16 payments
A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) $91,114 2 payments
PoCP study Phase Ib of NR2B modulation in MDD $37,360 5 payments
A Phase 3b/4 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Verify the Clinical Benefit of Aducanumab (BIIB037) in Participants With Alzheimer's Disease $8,043 1 payment
Connex 1 $4,140 15 payments
BI 425809 Pivotal efficacy study 1 $3,801 4 payments
A Phase 2, Randomized, Double-Blind, Multiple-Dose, Placebo-Controlled Study to Evaluate the Safety and Efficacy of BIIB104 in Subjects With Cognitive Impairment Associated With Schizophrenia (CIAS) $2,615 1 payment
Phase II dose finding trial in monotherapy for MDD $1,145 2 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.